form_8k.htm
 
 
 
 
 

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

________________
 
FORM 8-K
________________
 
CURRENT REPORT
 
Pursuant to Section 13 OR 15(d) of
the Securities Exchange Act of 1934
 
Date of Report (Date of Earliest Event Reported):  December 14, 2009
 
Micrus Endovascular Corporation
(Exact name of registrant as specified in its charter)
 
 

Delaware
  
000-51323
  
23-2853441
(State or other jurisdiction
  
(Commission File Number)
  
(IRS Employer
of incorporation)
      
Identification No.)

821 Fox Lane, San Jose, California
  
95131
(Address of principal executive offices)
  
(Zip Code)

 
(408) 433-1400
(Registrant’s telephone number, including area code)
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o           Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o           Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o           Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o           Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 


 
 
 

 
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
    
  On December 14, 2009, Michael Henson, a member of the board of directors of Micrus Endovascular Corporation (the “Company”), notified the Company that he intends to resign from the Company’s board of directors effective December 31, 2009.


 
 
 

 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
         
 
MICRUS ENDOVASCULAR CORPORATION
(Registrant)
 
  
Date: December 17, 2009 
By:  
/s/ Gordon T. Sangster
  
   
Gordon T. Sangster
  
   
Chief Financial Officer